Literature DB >> 34873852

Circulating tumor cell count: A reliable biomarker for treatment selection in metastatic breast cancer.

Bingzhen Li1, Ying Zheng2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34873852      PMCID： PMC8758428          DOI： 10.1111/1759-7714.14269

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN： 1759-7706            Impact factor:   3.500


× No keyword cloud information.
  15 in total

Review 1.  Tamoxifen in the treatment of breast cancer.

Authors:  C K Osborne
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

2.  Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Ann H Partridge; R Bryan Rumble; Lisa A Carey; Steven E Come; Nancy E Davidson; Angelo Di Leo; Julie Gralow; Gabriel N Hortobagyi; Beverly Moy; Douglas Yee; Shelley B Brundage; Michael A Danso; Maggie Wilcox; Ian E Smith
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

3.  Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.

Authors:  Costanza Paoletti; Maria C Muñiz; Dafydd G Thomas; Kent A Griffith; Kelley M Kidwell; Nahomi Tokudome; Martha E Brown; Kimberly Aung; M Craig Miller; Dorothy L Blossom; Anne F Schott; N Lynn Henry; James M Rae; Mark C Connelly; David A Chianese; Daniel F Hayes
Journal:  Clin Cancer Res       Date:  2014-11-07       Impact factor: 12.531

4.  Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.

Authors:  Elisa Gobbini; Monia Ezzalfani; Véronique Dieras; Thomas Bachelot; Etienne Brain; Marc Debled; William Jacot; Marie Ange Mouret-Reynier; Anthony Goncalves; Florence Dalenc; Anne Patsouris; Jean Marc Ferrero; Christelle Levy; Veronique Lorgis; Laurence Vanlemmens; Claudia Lefeuvre-Plesse; Simone Mathoulin-Pelissier; Thierry Petit; Lionel Uwer; Christelle Jouannaud; Marianne Leheurteur; Magali Lacroix-Triki; Audrey Lardy Cleaud; Mathieu Robain; Coralie Courtinard; Christian Cailliot; David Perol; Suzette Delaloge
Journal:  Eur J Cancer       Date:  2018-04-13       Impact factor: 9.162

5.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Authors:  Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes
Journal:  N Engl J Med       Date:  2004-08-19       Impact factor: 91.245

6.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Authors:  François-Clément Bidard; Dieter J Peeters; Tanja Fehm; Franco Nolé; Rafael Gisbert-Criado; Dimitrios Mavroudis; Salvatore Grisanti; Daniele Generali; Jose A Garcia-Saenz; Justin Stebbing; Carlos Caldas; Paola Gazzaniga; Luis Manso; Rita Zamarchi; Angela Fernandez de Lascoiti; Leticia De Mattos-Arruda; Michail Ignatiadis; Ronald Lebofsky; Steven J van Laere; Franziska Meier-Stiegen; Maria-Teresa Sandri; Jose Vidal-Martinez; Eleni Politaki; Francesca Consoli; Alberto Bottini; Eduardo Diaz-Rubio; Jonathan Krell; Sarah-Jane Dawson; Cristina Raimondi; Annemie Rutten; Wolfgang Janni; Elisabetta Munzone; Vicente Carañana; Sofia Agelaki; Camillo Almici; Luc Dirix; Erich-Franz Solomayer; Laura Zorzino; Helene Johannes; Jorge S Reis-Filho; Klaus Pantel; Jean-Yves Pierga; Stefan Michiels
Journal:  Lancet Oncol       Date:  2014-03-11       Impact factor: 41.316

7.  Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).

Authors:  Ji-Yeon Kim; Seri Park; Seock-Ah Im; Sung-Bae Kim; Joohyuk Sohn; Keun Seok Lee; Yee Soo Chae; Ki Hyeong Lee; Jee Hyun Kim; Young-Hyuck Im; Tae-Yong Kim; Kyung-Hun Lee; Jin-Hee Ahn; Gun Min Kim; In Hae Park; Soo Jung Lee; Hye Sook Han; Se Hyun Kim; Kyung Hae Jung; Yeon Hee Park
Journal:  Cancer Commun (Lond)       Date:  2019-05-28

8.  Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?

Authors:  Rui-Mei Feng; Yi-Nan Zong; Su-Mei Cao; Rui-Hua Xu
Journal:  Cancer Commun (Lond)       Date:  2019-04-29

9.  Cancer burden of major cancers in China: A need for sustainable actions.

Authors:  Maomao Cao; He Li; Dianqin Sun; Wanqing Chen
Journal:  Cancer Commun (Lond)       Date:  2020-05-02

10.  Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

Authors:  François-Clément Bidard; William Jacot; Nicolas Kiavue; Sylvain Dureau; Amir Kadi; Etienne Brain; Thomas Bachelot; Hugues Bourgeois; Anthony Gonçalves; Sylvain Ladoire; Hervé Naman; Florence Dalenc; Joseph Gligorov; Marc Espié; George Emile; Jean-Marc Ferrero; Delphine Loirat; Sophie Frank; Luc Cabel; Véronique Diéras; Laure Cayrefourcq; Cécile Simondi; Frédérique Berger; Catherine Alix-Panabières; Jean-Yves Pierga
Journal:  JAMA Oncol       Date:  2021-01-01       Impact factor: 31.777
View more
  1 in total

1.  The Prognostic Value of the Circulating Tumor Cell-Based Four mRNA Scoring System: A New Non-Invasive Setting for the Management of Bladder Cancer.

Authors:  Consuelo Amantini; Federica Maggi; Jacopo Adolfo Rossi de Vermandois; Marilena Gubbiotti; Antonella Giannantoni; Ettore Mearini; Massimo Nabissi; Daniele Tomassoni; Giorgio Santoni; Maria Beatrice Morelli
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.